NCT00286325View on ClinicalTrials.gov

Rituximab in the Treatment of Patients With Bullous Pemphigoid

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Bullous Pemphigoid

Interventions

DRUG

Rituximab

Infusion of 1000 mg of rituximab on day 0 and day 14

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Duke University

OTHER